



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED INCOME STATEMENT  
FOR THE YEAR ENDED 31 DECEMBER 2009**

	INDIVIDUAL PERIOD		CUMULATIVE PERIOD	
	CURRENT YEAR QUARTER 31/12/2009 RM'000	PRECEDING YEAR CORRESPONDING QUARTER 31/12/2008 RM'000	CURRENT YEAR TO DATE 31/12/2009 RM'000	PRECEDING YEAR CORRESPONDING PERIOD 31/12/2008 RM'000
Revenue	29,850	29,484	123,766	122,872
Cost of Sales	(14,607)	(17,291)	(61,876)	(62,242)
<b>Gross Profit</b>	<b>15,243</b>	<b>12,193</b>	<b>61,890</b>	<b>60,630</b>
Other operating income	125	217	759	2,624
Distribution costs	(2,889)	(4,251)	(11,379)	(14,221)
Administration expenses	(2,764)	(3,105)	(9,830)	(9,696)
Other operating expenses	(1,092)	(1,429)	(3,182)	(3,951)
<b>Profit from operations</b>	<b>8,623</b>	<b>3,625</b>	<b>38,258</b>	<b>35,386</b>
Finance costs	(13)	(13)	(43)	(46)
Share of profit after tax of associated company.	-	-	-	-
<b>Profit before taxation</b>	<b>8,610</b>	<b>3,612</b>	<b>38,215</b>	<b>35,340</b>
Taxation	(766)	(95)	(7,982)	(7,937)
<b>Profit after tax for the period</b>	<b>7,844</b>	<b>3,517</b>	<b>30,233</b>	<b>27,403</b>
<b>Attributable to:</b>				
Shareholders of the Company	7,844	3,517	30,233	27,403
Minority interest	-	-	-	-
<b>Profit after tax for the period</b>	<b>7,844</b>	<b>3,517</b>	<b>30,233</b>	<b>27,403</b>
Earnings per share (sen)				
Basic (based on weighted average)	<b>5.65</b>	<b>2.53</b>	<b>21.78</b>	<b>19.74</b>
Diluted (based on weighted average)	<b>5.65</b>	<b>2.53</b>	<b>21.78</b>	<b>19.74</b>

(The Condensed Consolidated Income Statement should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2008 and the accompanying explanatory notes attached to the interim financial statements.)



**CCM DUOPHARMA BIOTECH BERHAD (524271-W)**

(Incorporated in Malaysia)

**UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEET  
AS AT 31 DECEMBER 2009**

	AS AT END OF CURRENT PERIOD 31/12/2009 RM'000	AS AT PRECEDING FINANCIAL YEAR ENDED 31/12/2008 RM'000
<b>ASSETS</b>		
Property, Plant and Equipment	74,840	55,369
Investment Property	-	-
<b>Total non-current assets</b>	<u>74,840</u>	<u>55,369</u>
Inventories	36,353	33,581
Trade & Other Receivables	34,085	32,173
Related Company	1,023	1,681
Current tax assets	63	1,021
Assets classified as held for sale	-	8,131
Cash & Cash Equivalents	26,999	18,424
<b>Total current assets</b>	<u>98,523</u>	<u>95,011</u>
<b>Total Assets</b>	<u><b>173,363</b></u>	<u><b>150,380</b></u>
<b>EQUITY</b>		
Share Capital	69,739	69,739
Reserves	74,577	62,391
Treasury Shares	(1,578)	(1,578)
<b>Total Equity</b>	<u>142,738</u>	<u>130,552</u>
<b>LIABILITIES</b>		
Deferred Tax Liability	4,466	3,787
Long Term Borrowings	9,176	-
<b>Total non-current liabilities</b>	<u>13,642</u>	<u>3,787</u>
Trade & Other Payables	9,033	10,081
Amount due to related company	1,034	5,304
Provision	666	656
Term Loan	6,250	-
<b>Total current liabilities</b>	<u>16,983</u>	<u>16,041</u>
<b>Total Liabilities</b>	<u><b>30,625</b></u>	<u><b>19,828</b></u>
<b>Total Equity &amp; Liabilities</b>	<u><b>173,363</b></u>	<u><b>150,380</b></u>
<b>Net assets per share (RM)</b>	<b>1.02</b>	<b>0.94</b>

(The Condensed Consolidated Balance Sheet should be read in conjunction with the Audited Financial Statements for the year ended 31 December 2008 and the accompanying explanatory notes attached to the interim financial statements.)